ClinicalTrials.gg
CompletedNCT00093288Updated Sep 2, 2013

Major Depressive Disorder In The Elderly

A Phase 3 interventional study of bupropion XL in Depressive Disorder, Major, sponsored by GlaxoSmithKline. Completed at 16 sites in 6 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2013-09-02.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
364
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies testing bupropion in Depressive Disorder, Major — 1 open to participants now, 3 under way, none of them phase 3. Bupropion · Depressive Disorder, Major.

Enrollment
6th of 37
364 · median 74
Started
2004
with 3 others
Phase 3
7 of 37
none open now
Registered
3rd of 37
by date
Lead sponsor
5 of 37
GlaxoSmithKline

Among the 37 studies testing bupropion in Depressive Disorder, Major, this one is the 6th largest by enrollment, is one of 4 that started in 2004, is one of 7 in phase 3, and was the 3rd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 37 studies testing bupropion in Depressive Disorder, Major is open now. Recruiting first, the newest first:

About bupropion

Bupropion: first FDA approval 1985 (WELLBUTRIN), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing bupropion in Depressive Disorder, Major, or all of them as a file.
02

Study summary

This is a placebo-controlled study evaluating the effectiveness of medication in elderly subjects with Major Depressive Disorder (MDD).

03

Conditions studied

  • Depressive Disorder, Major

Keywords

  • MDD
  • bupropion
  • Depression
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Primary diagnosis of Major Depressive Disorder with criteria for their current episode for at least 8 weeks.

Exclusion criteria

Exclusion Criteria:

  • Patient has current or past history of seizure disorder or brain injury.
  • Patient has a diagnosis of anorexia or bulimia within the past 12 months.
  • Patient has a past or current DMS-IV diagnosis of schizophrenia or any other psychotic disorder(s).
  • Patient has had a myocardial infarction within 1 year or a history of uncontrolled hypertension or unstable heart disease with 6 months.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
364 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Montgomery-Asberg Depression Rating Scale

Secondary outcomes

  1. Montgomery-Asberg Depression Rating Scale Clinical Global Impression Improvement Scale Clinical Global Impression Severity Scale Hamilton Anxiety Rating Scale

07

Study locations

16 sites
  • GSK Investigational Site
    Caboolture, Queensland 4510, Australia
  • GSK Investigational Site
    Everton Park, Queensland 4053, Australia
  • GSK Investigational Site
    New Farm, Queensland 4005, Australia
  • GSK Investigational Site
    St. Albans, Victoria 3021, Australia
  • GSK Investigational Site
    Liège, 4000, Belgium
  • GSK Investigational Site
    Mont-Godinne, 5530, Belgium
  • GSK Investigational Site
    Montignies-sur-Sambre, 6061, Belgium
  • GSK Investigational Site
    Mikkeli, 50100, Finland
  • GSK Investigational Site
    Amersfoort, 3818 ES, Netherlands
  • GSK Investigational Site
    Grubbenvorst, 5971 BB, Netherlands
  • GSK Investigational Site
    Hilversum, 1211 PA, Netherlands
  • GSK Investigational Site
    Hoogvliet, 3192 JN, Netherlands
  • GSK Investigational Site
    Wildervank, 9648 BE, Netherlands
  • GSK Investigational Site
    Oslo, 0407, Norway
  • GSK Investigational Site
    Moscow, 115522, Russian Federation
  • GSK Investigational Site
    Moscow, 119992, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2004, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2004
First posted
Oct 7, 2004
Start
Jun 2004
Primary completionActual
Oct 2005
CompletionActual
Oct 2005
Last update
Sep 2, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00093288
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 7, 2004
Start date
Jun 2004
Primary completion
Oct 2005
Completion
Oct 2005
Last update
Sep 2, 2013

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupropion

Start the discussion